Spots Global Cancer Trial Database for Moderately Hypofractionated Adaptive Radiotherapy for Cervical Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Moderately Hypofractionated Adaptive Radiotherapy for Cervical Cancer

Official Title: Clinical Research of Moderately Hypofractionated Radiotherapy for Cervical Cancer

Study ID: NCT05994300

Conditions

Cervical Neoplasm

Adaptive Radiotherapy

Radiotherapy; Adverse Effect

Interventions

Moderately hypofractionated adaptive radiotherapy (ART)+ High-dose rate (HDR) Brachytherapy

Study Description

Brief Summary: External radiation given in 25 fractions or so together with weekly chemotherapy and followed by 5 or 6 fractions of brachytherapy is the standard of care for patients with locally advanced cervical cancer. We hope to develop external moderately hypofractionated radiotherapy of cervical cancer based on adaptive radiotherapy.The objective of this study is to evaluate the efficacy and treatment-related toxicity of moderately hypofractionated adaptive radiotherapy in the treatment of cervical cancer.

Detailed Description: This is an investigator-initiated efficacious, single-center, open-label clinical trial study. This study hypothesizes that the use of external moderately hypofractionated radiotherapy of cervical cancer based on adaptive radiotherapy. A dose of 43.35Gy in 17 fractions is delivered to clinical target volume (CTV). Patients receive cisplatin based concurrent chemotherapy. The primary endpoint is acute toxicity.